[1] In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion

[2] Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus

[3] Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

[4] Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus

[5] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

[6] Recombinant respiratory syncytial virus from which the entire SH gene has been deleted grows efficiently in cell culture and exhibits site-specific attenuation in the respiratory tract of the mouse

[7] Safety and immunogenicity of a subunit respiratory syncytial virus vaccine in children 24 to 48 months old

[8] An ultrastructural study of the interaction of human eosinophils with respiratory syncytial virus

[9] Testing models predicting severity of respiratory syncytial virus infection on the PICNIC RSV database. Pediatric Investigators Collaborative Network on Infections in Canada

[10] Respiratory syncytial virus infection: immune response, immunopathogenesis, and treatment

[11] Second-year surveillance of recipients of a respiratory syncytial virus (RSV) F protein subunit vaccine, PFP-1: evaluation of antibody persistence and possible disease enhancement

[12] Respiratory syncytial virus (RSV) immune globulin intravenous therapy for RSV lower respiratory tract infection in infants and young children at high risk for severe RSV infections: Respiratory Syncytial Virus Immune Globulin Study Group

[13] Respiratory syncytial virus (RSV) SH and G proteins are not essential for viral replication in vitro: clinical evaluation and molecular characterization of a cold-passaged, attenuated RSV subgroup B mutant

[14] Respiratory syncytial virus immune globulin intravenous: indications for use. American Academy of Pediatrics Committee on Infectious Diseases, Committee on Fetus and Newborn

[15] Rapid and sensitive method using multiplex real-time PCR for diagnosis of infections by influenza a and influenza B viruses, respiratory syncytial virus, and parainfluenza viruses 1, 2, 3, and 4

[16] Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

[17] Right and left ventricular function in hospitalized children with respiratory syncytial virus infection

[18] Analytical performances of the BD Veritor™ System for the detection of respiratory syncytial virus and influenzaviruses A and B when used at bedside in the pediatric emergency department.

[19] Development of a reverse transcription recombinase polymerase amplification assay for rapid detection of human respiratory syncytial virus.

[20] Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze

[21] The Changes of Th17/Treg and Related Cytokines: IL-17, IL-23, IL-10, and TGF-β in Respiratory Syncytial Virus Bronchiolitis Rat Model.

[22] Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series.

[23] Global respiratory syncytial virus-associated mortality in young children (RSV GOLD): a retrospective case series

[24] Pathogenesis of Respiratory Syncytial Virus Infection in BALB/c Mice Differs Between Intratracheal and Intranasal Inoculation.

[25] Epidemic dynamics of respiratory syncytial virus in current and future climates.

[26] Correction to: Blocking of opioid receptors in experimental formaline-inactivated respiratory syncytial virus (FI-RSV) immunopathogenesis: from beneficial to harmful impacts (Medical Microbiology and Immunology, (2018), 207, 2, (105-115), 10.1007/s00430-017-0531-0)

[27] Contribution of Dendritic Cells in Protective Immunity against Respiratory Syncytial Virus Infection.

[28] Evaluation of respiratory syncytial virus IgG antibody dynamics in mother-infant pairs cohort.

[29] Disease severity of respiratory syncytial virus (RSV) infection correlate to a novel set of five amino acid substitutions in the RSV attachment glycoprotein (G) in China.

[30] Multiple Respiratory Syncytial Virus Introductions Into a Neonatal Intensive Care Unit.

[31] Evaluation of the protective efficacy of reshaped human monoclonal antibody RSHZ19 against respiratory syncytial virus in cotton rats

[32] An outbreak of febrile illness and pneumonia associated with respiratory syncytial virus infection

[33] Quantitative shedding patterns of respiratory syncytial virus in infants

[34] Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses.

[35] Passive transfer of respiratory syncytial virus (RSV) antiserum suppresses the immune response to the RSV fusion (F) and large (G) glycoproteins expressed by recombinant vaccinia viruses

[36] Transcriptional mapping of human respiratory syncytial virus.

[37] The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species.

[38] Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies.

[39] Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo

[40] RNA replication by respiratory syncytial virus (RSV) is directed by the N, P, and L proteins; transcription also occurs under these conditions but requires RSV superinfection for efficient synthesis of full-length mRNA.

[41] Demonstration that glycoprotein G is the attachment protein of respiratory syncytial virus

[42] Clinical experience with aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

[43] Pathogenesis of Severe Acute Respiratory Infections in the Developing World: Respiratory Syncytial Virus and Parainfluenza Viruses

[44] Transcriptional mapping of human respiratory syncytial virus

[45] Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine

[46] Speculation on Pathogenesis in Death from Respiratory Syncytial Virus Infection

[47] Risk factors of severe hospitalized respiratory syncytial virus infection in tertiary care center in Thailand

[48] Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order.

[49] Aerosolized immunoglobulin treatment of respiratory syncytial virus infection in infants

[50] Activation of human eosinophils in vitro by respiratory syncytial virus

[51] Epidemiology of respiratory syncytial virus infection in Washington, D.C. I. Importance of the virus in different respiratory tract disease syndromes and temporal distribution of infection

[52] Reinfection of mice with respiratory syncytial virus

[53] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation.

[54] Virus-specific CD8+ T Lymphocytes Downregulate T Helper Cell Type 2 Cytokine Secretion and Pulmonary Eosinophilia during Experimental Murine Respiratory Syncytial Virus Infection

[55] Aerosolized ribavirin in mechanically ventilated children with respiratory syncytial virus lower respiratory tract disease: a prospective, double-blind, randomized trial

[56] Immunity and immunopathology to respiratory syncytial virus. The mouse model

[57] Dissociation between serum neutralizing and glycoprotein antibody responses of infants and children who received inactivated respiratory syncytial virus vaccine.

[58] Phase I study of intravenous ribavirin treatment of respiratory syncytial virus pneumonia after marrow transplantation

[59] Analysis of the local and systemic immune responses induced in BALB/c mice by experimental respiratory syncytial virus infection

[60] Epidemiology of respiratory syncytial virus infection among infants and children in Chicago

[61] Ribavirin for respiratory syncytial virus lower respiratory tract infection. A systematic overview

[62] Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein

[63] Eosinophil cationic protein in nasopharyngeal secretions and serum of infants infected with respiratory syncytial virus

[64] Comparison of antibody concentrations and protective activity of respiratory syncytial virus immune globulin and conventional immune globulin

[65] Virus-specific CD8+ T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection

[66] Recombinant human respiratory syncytial virus (RSV) monoclonal antibody Fab is effective therapeutically when introduced directly into the lungs of RSV-infected mice

[67] Systemic cell-mediated and antibody responses in infants with respiratory syncytial virus infections

[68] Reassessment of the indications for ribavirin therapy in respiratory syncytial virus infections. American Academy of Pediatrics Committee on Infectious Diseases

[69] Age related IgG subclass response to respiratory syncytial virus fusion protein in infected infants

[70] Purified fusion protein vaccine protects against lower respiratory tract illness during respiratory syncytial virus season in children with cystic fibrosis

[71] Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3-6 months after immunization

[72] The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins

[73] Priming immunization determines T helper cytokine mRNA expression patterns in lungs of mice challenged with respiratory syncytial virus

[74] Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus

[75] Effectiveness of ribavirin in otherwise well infants with respiratory syncytial virus-associated respiratory failure. Pediatric Critical Study Group

[76] Studies of passive immunotherapy for infections of respiratory syncytial virus in the respiratory tract of a primate model

[77] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in ambulatory adults over age 60

[78] Transcription elongation factor of respiratory syncytial virus, a nonsegmented negative-strand RNA virus

[79] EPIDEMIOLOGY OF RESPIRATORY SYNCYTIAL VIRUS INFECTION AMONG INFANTS AND CHILDREN IN CHICAGO

[80] Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections

[81] Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein.

[82] Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection

[83] The 1A protein of respiratory syncytial virus is an integral membrane protein present as multiple, structurally distinct species

[84] Recombinant superoxide dismutase (SOD) administered by aerosol inhibits respiratory syncytial virus infection in cotton rats

[85] Safety and immunogenicity of a respiratory syncytial virus subunit vaccine (PFP-2) in the institutionalized elderly

[86] Potent inhibition of respiratory syncytial virus by polyoxometalates of several structural classes

[87] Effect of age and preexisting antibody on serum antibody response of infants and children to the F and G glycoproteins during respiratory syncytial virus infection.

[88] Cytotoxic T-cell response to respiratory syncytial virus in mice.

[89] Resistance to respiratory syncytial virus (RSV) challenge induced by infection with a vaccinia virus recombinant expressing the RSV M2 protein (Vac-M2) is mediated by CD8+ T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies

[90] A controlled trial of aerosolized ribavirin in infants receiving mechanical ventilation for severe respiratory syncytial virus infection

[91] Development of cell-mediated cytotoxic immunity to respiratory syncytial virus in human infants following naturally acquired infection

[92] Nucleotide sequences for the gene junctions of human respiratory syncytial virus reveal distinctive features of intergenic structure and gene order

[93] Cell-mediated cytotoxic response to respiratory syncytial virus in infants with bronchiolitis

[94] Fatal respiratory syncytial virus infection in severe combined immunodeficiency syndrome

[95] Enzyme-linked immunosorbent assay for measurement of serological response to respiratory syncytial virus infection

[96] The immunologic response to infection with respiratory syncytial virus in infants

[97] Monoclonal antibodies to respiratory syncytial virus proteins: identification of the fusion protein

[98] Cytotoxic T cells clear virus but augment lung pathology in mice infected with respiratory syncytial virus

[99] Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion

[100] Hyperimmune globulins in prevention and treatment of respiratory syncytial virus infections.

[101] Immunopathologic mechanisms in lower respiratory tract disease of infants due to respiratory syncytial virus